| Bioactivity | D-685, a prodrug of D-520, exhibits higher in vivo anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model than the parent D-520. D-685 reduces accumulation of human α-synuclein (α-syn) protein. D-685 exhibits facile brain penetration[1]. |
| In Vivo | D-685 (12 mg/kg; 每天腹腔注射; 持续 1 个月) 减少 α-Syn tg 小鼠中 α-突触核蛋白的积累[1]。 与单独使用利血平 (HY-N0480; 5.0 mg/kg; 皮下注射) 治疗相比，D-685 (10 μmol/kg; 腹腔注射) 在逆转 Sprague-Dawley 大鼠 (体重 220-225 g 的雄性和雌性) 的运动不能方面非常有效 ，同时显着增强在整个 6 小时研究期间运动[1]。 D-685 在腹腔给药下表现出容易渗透到大脑中，具有高脑血浆比 (B/P: 4)[1]。 Animal Model: |
| Name | D-685 |
| Formula | C32H39N3O3 |
| Molar Mass | 513.67 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Aloke K Dutta, et al. D-685 Reverses Motor Deficits and Reduces Accumulation of Human α-Synuclein Protein in Two Different Parkinson's Disease Animal Models. ACS Chem Neurosci. 2023 Mar 1;14(5):885-896. |